Anandamide (an endocannabinoid) and other bioactive long-chain NAEs (N-acylethanolamines) are formed by direct release from N-acyl-PE (N-acyl-phosphatidylethanolamine) by a PLD (phospholipase D). However, the possible presence of a two-step pathway from N-acyl-PE has also been suggested previously, which comprises (1) the hydrolysis of N-acyl-PE to N-acyl-lysoPE by PLA 1 /PLA 2 enzyme(s) and (2) the release of NAEs from N-acyllysoPE by lysoPLD (lysophospholipase D) enzyme(s). In the present study we report for the first time the characterization of enzymes responsible for this pathway. The PLA 1 /PLA 2 activity for N-palmitoyl-PE was found in various rat tissues, with the highest activity in the stomach. This stomach enzyme was identified as group IB sPLA 2 (secretory PLA 2 ), and its product was determined as N-acyl-1-acyl-lysoPE. Recombinant group IB, IIA and V of sPLA 2 s were also active with N-palmitoyl-PE, whereas group X sPLA 2 and cytosolic PLA 2 α were inactive. In addition, we found wide distribution of lysoPLD activity generating N-palmitoylethanolamine from N-palmitoyl-lysoPE in rat tissues, with higher activities in the brain and testis. Based on several lines of enzymological evidence, the lysoPLD enzyme could be distinct from the known N-acyl-PE-hydrolysing PLD. sPLA 2 -IB dose dependently enhanced the production of N-palmitoylethanolamine from N-palmitoyl-PE in the brain homogenate showing the lysoPLD activity. N-Arachidonoyl-PE and N-arachidonoyl-lysoPE as anandamide precursors were also good substrates of sPLA 2 -IB and the lysoPLD respectively. These results suggest that the sequential actions of PLA 2 and lysoPLD may constitute another biosynthetic pathway for NAEs, including anandamide.
INTRODUCTION
Ethanolamides of long-chain fatty acids, collectively referred to as NAEs (N-acylethanolamines), are present in various mammalian tissues [1] [2] [3] [4] [5] . NAEs were previously reported to have anti-inflammatory and membrane-stabilizing actions, and noted to markedly increase in degenerating tissues and cells [6] [7] [8] [9] . Later, N-arachidonoylethanolamine (anandamide) was identified as an endogenous ligand of the cannabinoid receptors [10] and vanilloid receptor [11] , and shown to exert various cannabimimetic activities [12] . In contrast, NAEs with a saturated or monounsaturated fatty acid did not activate cannabinoid receptors, but they were shown to possess various biological activities. For example, N-palmitoylethanolamine was reported to be anti-inflammatory and anti-nociceptive [13] [14] [15] , N-oleoylethanolamine to be anorexic via peroxisome-proliferator-activated receptor-α [16, 17] , and N-stearoylethanolamine to be pro-apoptotic [18] .
It is generally accepted that NAE is principally biosynthesized in animal tissues from PE (phosphatidylethanolamine) by two sequential enzyme reactions [1] [2] [3] [4] [5] 19] . The first reaction is transfer of an acyl-group from the sn-1 position of glycerophospholipid to PE by an acyltransferase, resulting in the generation of N-acyl-PE. Subsequently, NAE is released from N-acyl-PE by a phosphodiesterase of PLD (phospholipase D), which we recently cloned [20] .
Abbreviations used: LPA, lysophosphatidic acid; lysoPLD; lysophospholipase D; MAFP, methyl arachidonyl fluorophosphonate; NAE, N-acylethanolamine; PE, phosphatidylethanolamine; PL, phospholipase; cPLA 2 α, cytosolic PLA 2 α; sPLA 2 , secretory PLA 2 .
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In addition to this direct release of NAE by PLD, Natarajan et al. [21] suggested previously an alternative biosynthetic pathway containing two-step reactions from N-acyl-PE to NAE. In this pathway, shown in Scheme 1, N-acyl-PE is first hydrolysed to N-acyl-lysoPE and a non-esterified fatty acid by an enzyme having PLA 1 or PLA 2 activity, and NAE is then released from N-acyl-lysoPE by a lysoPLD (lysophospholipase D)-like enzyme. The PLA 1 -or PLA 2 -catalysed reaction of this pathway was suggested by the previous observation that N-acyl-lysoPE was detected as a catabolite from radiolabelled N-acyl-PE in the homogenates of rat heart, rat brain and dog brain [21] [22] [23] . It is also noted that commercially available venom and pancreatic PLA 2 s have been used to prepare radiolabelled N-acyl-lysoPE from radiolabelled N-acyl-PE [21, 22, 24] . The occurrence of a lysoPLD-like enzyme producing NAE was suggested by the finding that radiolabelled N-acyl-lysoPE was hydrolysed to NAE by the microsomal preparations of rat heart and dog brain [21, 22] . However, enzymes responsible for this alternative pathway in the animal tissues have been hardly characterized, and the precise chemical structure of N-acyl-lysoPE has not been determined. It also remained unknown whether N-acyl-lysoPE-hydrolysing lysoPLD was identical to the PLD directly hydrolysing N-acyl-PE.
In the present study, in order to clarify the physiological significance of this NAE biosynthetic pathway via N-acyl-lysoPE,
Scheme 1 Diagram of the biosynthetic pathways of anandamide
The PLA 1 /PLA 2 -lysoPLD pathway and the confirmed PLD pathway are shown. PA, phosphatidic acid.
we focused on the related enzymes. The results suggest the involvement of several, but not all, PLA 2 isoenzymes in the synthesis of NAEs, including anandamide. Moreover, we propose the existence of lysoPLD distinct from the known PLD acting on N-acyl-PE. ]arachidonoyl-PE respectively, using rat stomach sPLA 2 -IB (secretory PLA 2 -IB) purified as described below. The products were purified by TLC with a mixture of chloroform/methanol/28 % ammonium hydroxide (40:10:1, by vol.) or chloroform/methanol/acetic acid (9:1:1, by vol.).
Preparation of enzymes
Male Wistar rats (250-500 g, Charles River Japan) were anesthetized by diethyl ether and killed by cervical dislocation. Various organs were removed, cut into small pieces and then homogenized in 5 times the volume (v/w) of 20 mM ice-cold Tris/HCl (pH 7.4) containing 0.32 M sucrose with a Polytron homogenizer. The homogenates were centrifuged at 800 g for 15 min and the resultant supernatant was used in the experiments shown in Figures 1, 4 and 6. For the experiments shown in Figure 5 , the 800 g supernatants of rat heart and brain were further centrifuged at 105 000 g for 50 min, and the obtained pellets (particulate fractions) were suspended in 20 mM Tris/HCl (pH 7.4). The particulate fractions were then treated with 1 % (w/v) octyl glucoside, and the supernatant obtained by further centrifugation at 105 000 g for 50 min was used as solubilized proteins. Protein concentration was determined by the method of Bradford [25] with BSA as a standard.
Purification of the stomach PLA 2 Rat stomach was homogenized in 9 times the volume (v/w) of 20 mM ice-cold Tris/HCl (pH 7.4) containing 0.32 M sucrose, and its particulate fraction was prepared as described above. The particulate fraction suspended in 20 mM Tris/HCl (pH 7.4) was subjected to one cycle of freezing and thawing, solubilized by 1 % (w/v) octyl glucoside, and centrifuged at 105 000 g for 50 min. The resultant supernatant was heated at 70
• C for 10 min, and the developed precipitate was removed by centrifugation at 105 000 g for 50 min. The supernatant (4.5 mg of protein) was 10-fold diluted with water and loaded on to a Macro-Prep High Q anion-exchange column (bed volume, 3 ml) pre-equilibrated with 20 mM Tris/HCl (pH 7.4). The pass-through fractions containing the enzyme were then loaded on to a HiTrap SP HP cation-exchange column (bed volume, 5 ml) preequilibrated with 20 mM Tris/HCl (pH 7.4) containing 0.1 % (w/v) octyl glucoside (buffer A). After washing the column with 15 ml of buffer A, the enzyme was eluted with 5 ml of buffer A containing 50 mM NaCl. Prepared purified enzyme was then stored at − 80
• C until use.
Protein sequencing
The purified stomach enzyme was concentrated by a centrifugal filter device (Microcon YM-10), subjected to SDS/PAGE (12.5 % gel), and electrotransferred on to a hydrophobic PVDF membrane (Hybond-P). The band stained with Coomassie Brilliant Blue R-250 was excised, and its N-terminal sequence was determined with a Procise Model 492 protein sequencer (Applied Biosystems, Foster City, CA, U.S.A.).
Expression of recombinant PLA 2 s
HEK-293 cells were cultured in RPMI medium 1640 containing 10 % fetal calf serum. As described previously, the cDNAs for rat sPLA 2 -IB [26] and human sPLA 2 -X [27] were subcloned into pCR3.1, the cDNAs for human sPLA 2 -IIA [28] and human sPLA 2 -V [26] into pRc/CMV, and mouse cPLA 2 α (cytosolic PLA 2 α) cDNA into pBK-CMV [28, 29] . Transfection was performed according to the manufacturer's instruction: 8-16 µg of plasmid was mixed with 32 µl of LipofectAMINE Plus TM in 800 µl of serum-free RPMI medium 1640 for 30 min and then added to cells that had attained approx. 70 % confluence in a 10 cm dish containing 8 ml of serum-free RPMI medium 1640. After incubation for 4-6 h, the medium was removed, and the transfected cells were further cultured in the presence of serum for 66-68 h. Since sPLA 2 -IB and sPLA 2 -X were secreted outside the cells, the culture supernatants were used as the enzyme preparations. For cPLA 2 α, the cells were harvested with the aid of trypsin, washed twice, suspended in 10 mM Tris/HCl (pH 7.4) and 150 mM NaCl, and sonicated three times each for 3 s. The resultant cell lysate was used as the enzyme preparation. For sPLA 2 -IIA and sPLA 2 -V, after the culture medium was removed, the cells were incubated for 15 min at 37
• C with 5 ml of the culture medium containing 1 M NaCl. This procedure allowed the cell surface-associated sPLA 2 s to be recovered in the medium [28] , which was used for the enzyme assay.
Enzyme assay
For the PLA 2 assay with native rat enzymes, the enzymes were incubated with 100 µM or 200 µM 14 C-labelled substrate (1000 cpm/nmol, dissolved in 5 µl of ethanol) in 100 µl of 50 mM Tris/acetic acid (pH 8.0) containing 10 mM CaCl 2 at 37
• C for 5 min (for the purified stomach enzyme and the homogenates of stomach, pancreas, and small intestine) or 30 min (for the homogenates of other tissues). For the PLA 2 assay with recombinant PLA 2 s expressed in HEK-293 cells, the enzymes prepared as described above were incubated at 37
• C for 5 min (sPLA 2 -IB) or 30 min (other PLA 2 s) with 100 µM 14 C-labelled substrate (1000 cpm/nmol, dissolved in 5 µl of ethanol) in 100 µl of the following buffers for each PLA 2 isoenzyme: sPLA 2 -IB, 50 mM Tris/acetic acid (pH 8.0) containing 10 mM CaCl 2 ; sPLA 2 -IIA, 50 mM Tris/HCl (pH 9.0) containing 10 mM CaCl 2 ; sPLA 2 -V, 50 mM Tris/acetic acid (pH 6.0) containing 10 mM CaCl 2 ; sPLA 2 -X, 50 mM Tris/HCl (pH 7.4) containing 10 mM CaCl 2 ; and cPLA 2 α, 100 mM Tris/HCl (pH 9.0) containing 4 mM CaCl 2 [30] [31] [32] [33] . The reaction was terminated by the addition of 0.3 ml of a mixture of chloroform/methanol (2:1, v/v) containing 5 mM 3(2)-t-butyl-4-hydroxyanisole. In the assays to detect the radiolabelled non-esterified fatty acids produced, 25 µl of 1 M citric acid was included in the mixture to facilitate the extraction of the radiolabelled non-esterified fatty acid into the organic phase. After centrifugation, 100 µl of the organic phase was spotted on a silica gel thin-layer plate (10 cm height) and subjected to TLC at 4
• C for 25 min with a mixture of chloroform/methanol/28 % ammonium hydroxide (40:10:1, by vol.) to detect N-[
14 C]palmitoyl-lysoPE and N-[
14 C]arachidonoyl-lysoPE produced or with chloroform/ methanol/acetic acid (9:1:1, by vol.) to detect radiolabelled non-esterified fatty acids produced. Distribution of radioactivity on the plate was quantified by a BAS1500 bioimaging analyser (Fujix, Tokyo, Japan).
For the lysoPLD assay, the enzyme was incubated with 25- 
]arachidonoyllysoPE (1000 cpm/nmol, dissolved in 5 µl of ethanol) in 100 µl of 50 mM Tris/HCl (pH 8.0) at 37
• C for 30 min. The reaction was terminated by the addition of 0.3 ml of a mixture of chloroform/ methanol (2:1, v/v) containing 5 mM 3(2)-t-butyl-4-hydroxyanisole. TLC was performed with a mixture of chloroform/ methanol/28 % ammonium hydroxide (40:10:1, by vol.) at 4
• C for 25 min. All the enzyme assays were performed in triplicate.
RESULTS

Tissue distribution of N-acyl-PE-hydrolysing PLA 1 /PLA 2 activity
We first examined the N-acyl-PE-hydrolysing PLA 1 /PLA 2 activity with the homogenate of rat brain. The homogenate was allowed to react with N-[
14 C]palmitoyl-PE in the presence of 10 mM CaCl 2 , and the products were separated from the remaining substrate by TLC. The results revealed that the brain had PLA 1 /PLA 2 activity for converting N-[
14 C]palmitoyl-PE to N-[ 14 C]palmitoyl-lysoPE, in addition to the PLD activity hydrolysing the same substrate to N- [ 14 C]palmitoylethanolamine, in agreement with a previous report [24] . These reactions did not occur with the heat-treated homogenate. By this method, we examined the tissue distribution of the PLA 1 /PLA 2 activity for N-[
14 C]palmitoyl-PE in rat. The results showed a wide distribution of the enzyme activity (Figure 1) . Among them, by far the highest activity was observed in stomach with a specific activity of 49.1 + − 3.5 nmol/min per mg of protein (means + − S.D., n = 3) at 37
• C, followed by pancreas (7.8 + − 0.2) and small intestine (1.4 + − 0.2). The other tested tissues showed lower activities (0.02-0.17 nmol/min per mg of protein).
Purification, identification and substrate specificity of stomach N-acyl-PE-hydrolysing PLA 1 /PLA 2 For the purpose of the identification of the stomach PLA 1 / PLA 2 , we attempted to purify the enzyme. After the solubilization of the enzyme from the particulate fraction by 1 % octyl glucoside, the protein sample was subjected sequentially to heat treatment at 70
• C for 10 min and two chromatographic steps using Macro-Prep High Q and HiTrap SP HP. Through this procedure the specific PLA 1 /PLA 2 activity with N-[
14 C]palmitoyl-PE was increased 472-fold from 71 nmol/min per mg of protein to 34 µmol/min per mg of protein (Table 1 ). The purified enzyme preparation gave a single protein band around 17 kDa, as analysed by SDS/PAGE. The N-terminal sequence of this 17-kDa protein was determined by Edman degradation as Ala-Val-Trp-GlnPhe-Arg-Asn-Met-Ile-Lys-Xaa-Thr-Ile-Pro-Gly-Ser-Asp. This sequence was identical to Ala 23 -Asp 39 of rat sPLA 2 -IB (assuming Xaa to be Cys) [34] . Thus we concluded that the purified stomach enzyme hydrolysing N-palmitoyl-PE was sPLA 2 -IB.
In order to determine which acyl group at sn-1 or sn-2 position of N-palmitoyl-PE was removed by the purified sPLA 2 -IB, we used two types of N-palmitoyl-PE in which a different carbon atom was radiolabelled. With N-[
14 C]palmitoyl-PE as the substrate of the purified sPLA 2 -IB, only N-[
14 C]palmitoyl-lysoPE was detected as the radiolabelled product by TLC (Figure 2A , lane 2). In contrast, the enzyme converted N-palmitoyl-2-[
14 C] linoleoyl-PE exclusively to radiolabelled linoleic acid (Figure 2A, lane 4) . Furthermore, both N-[
14 C]palmitoyl-lysoPE and Furthermore, the reactivity of the purified stomach sPLA 2 -IB with N-palmitoyl-PE was compared with that of PE, a general substrate of PLA 2 ( Figure 2B ). The results indicated that Npalmitoyl-2-[
14 C]linoleoyl-PE was as reactive as 2-[ 14 C]linoleoyl-PE both at 100 µM and 200 µM. We also assessed the reactivity with N-[
14 C]arachidonoyl-PE, a precursor of anandamide, which was also found to be an active substrate ( Figure 2C ).
Hydrolytic activity of various PLA 2 isoenzymes with N-palmitoyl-PE
We next examined whether PLA 2 isoenzymes, other than sPLA 2 -IB, were also able to act as PLA 2 toward N-acyl-PE. We expressed a series of representative PLA 2 isoenzymes in HEK-293 cells, and measured their activities with N-acyl-PE. We used group IB, IIA, 
Tissue distribution of N-acyl-lysoPE-hydrolysing lysoPLD activity
We found the lysoPLD activity releasing N-[
C]palmitoylethanolamine from N-[
14 C]palmitoyl-lysoPE in the homogenate of rat brain. This reaction did not occur with the heat-treated homogenate. When the homogenates were subjected to ultracentrifugation, most of the lysoPLD activity was recovered in the particulate fraction, rather than cytosol. When the particulate fraction was allowed to react with N-[
14 C]palmitoyl-lysoPE in a range of pH 4-11, the optimum pH was found to be around 8. The addition of 2 mM EDTA into the reaction mixture almost completely abolished the enzyme activity, suggesting the requirement for bivalent cations. However, the addition of 10 mM MgCl 2 did not stimulate the activity significantly, and 10 mM CaCl 2 inhibited the enzyme by 80 %. We therefore carried out the lysoPLD assay in Tris/HCl buffer at pH 8 without adding bivalent cations, and examined the tissue distribution of the lysoPLD activity toward N- [ 14 C]palmitoyl-lysoPE in rat. As shown in Figure 4 , the enzyme activities were widely distributed among various organs, with higher activities in the brain and testis.
Characterization of brain N-acyl-lysoPE-hydrolysing lysoPLD
MAFP, a serine hydrolase inhibitor, is reported to have little inhibitory effect on the heart N-acyl-PE-hydrolysing PLD at least up to 1 µM [23, 35] . In accordance with the previous result, MAFP had no effect on the brain PLD activity toward N-[ 14 C]palmitoyl-PE up to 3 µM ( Figure 5A ). The brain PLD activity was stimulated about 3-fold by 0.06 % Triton X-100 as was reported previously [22, 36] , and the Triton X-100-stimulated PLD activity was also insensitive to MAFP (results not shown). In contrast, MAFP dose dependently inhibited the lysoPLD activity of the brain particulate fraction toward N-[
14 C]palmitoyl-lysoPE with an IC 50 value of about 0.2 µM ( Figure 5A) .
N-Acyl-PE-hydrolysing PLD could be solubilized from rat heart microsomes with 1 % octyl glucoside [35, 36] . The rat brain PLD was also efficiently solubilized with the same detergent ( Figure 5B ). However, the N-[
14 C]palmitoyl-lysoPE-hydrolysing lysoPLD was only partially solubilized by the same procedure. These findings provided strong support for the presence of N-acyllysoPE-hydrolysing lysoPLD enzyme distinct from N-acyl-PEhydrolysing PLD in the rat brain.
We also examined the reactivity of rat brain lysoPLD with N-arachidonoyl-lysoPE, a precursor of anandamide. When varying concentrations (25- Figure 5C ).
Synthesis of N-palmitoylethanolamine by the sequential actions of sPLA 2 -IB and lysoPLD
Finally, we assessed whether N-palmitoylethanolamine could actually be synthesized by the combination of PLA 2 and lysoPLD. When we mixed increasing amounts of the purified stomach sPLA 2 ( Figure 6 ). In the presence of 1 µM MAFP to inhibit lysoPLD, such an increase in the generation of [ 14 C]palmitoylethanolamine was not observed (results not shown).
DISCUSSION
Recent progress in the studies on biological activities of anandamide and other NAEs urges us to investigate the regulatory mechanisms in the biosynthesis of NAEs. It is generally accepted that NAE is directly released from N-acyl-PE by PLD [1- 5, 19] . We recently cloned this PLD which is structurally and catalytically distinguishable from the known PLDs [20] . In addition, an alternative pathway via N-acyl-lysoPE has been suggested earlier [21] (Scheme 1). However, the enzymes involved have not been characterized. The present study focused on the enzymes responsible for this biosynthetic pathway of NAE from Nacyl-PE to N-acyl-lysoPE. We clarified that several PLA 2 isoenzymes can generate N-acyl-lysoPE from N-acyl-PE, and that lysoPLD releasing NAEs from N-acyl-lysoPE is catalytically distinct from the N-acyl-PE-hydrolysing PLD. The tissue distribution studies revealed the wide distributions of both of these two enzyme activities. The substrate specificity experiments showed that the precursors of anandamide are also the substrates of both the enzymes. Notably, in the brain particulate fraction, the specific activity of lysoPLD (0.31 nmol/min per mg of protein) was far greater than that of PLD (0.017 nmol/min per mg of protein) (Figure 5A ). In general, N-acyl-PE exists in a much higher amount than NAE in animal tissues [2] . Hence, upon the activation of sPLA 2 , NAEs including anandamide could be generated by this pathway. We showed that NAE was actually formed from N-acyl-PE by the combination of sPLA 2 -IB and lysoPLD (Figure 6 ). However, further investigation will be required to clarify how much this pathway contributes to the in vivo formation of NAEs.
Since the activity of N-palmitoyl-PE-hydrolysing PLA 1 /PLA 2 was by far the highest in stomach among the tested organs, we purified the enzyme to apparent homogeneity from stomach and identified it to be sPLA 2 -IB, that is the pancreatic-type PLA 2 . The identification was further confirmed by the finding that recombinant sPLA 2 -IB was also active with N-palmitoyl-PE. The high content of sPLA 2 -IB in rat stomach is in good agreement with the previous observation that sPLA 2 -IB is abundantly expressed in rat gastric mucosa [37] . Therefore, it seemed that the extremely high N-palmitoyl-PE-hydrolysing activity in stomach is mostly derived from sPLA 2 -IB. It is likely that N-acyl-PE in the diet is first digested mainly by sPLA 2 -IB in the gastrointestinal tract. The enzyme activity of stomach sPLA 2 -IB toward both PE and N-acyl-PE were similar between 100 µM and 200 µM of the substrate concentrations ( Figures 2B and 2C) , indicating that the standard enzyme assay with 100 µM of the substrate was performed near the saturation levels of the substrates.
We also demonstrated that the purified stomach sPLA 2 -IB cleaved N-palmitoyl-PE exclusively at sn-2 position to release a fatty acid. Accordingly, the N-palmitoyl-lysoPE produced by sPLA 2 -IB retains the acyl group at sn-1 position. However, we cannot rule out the possibility that PLA 1 and other phospholipases hydrolyse N-acyl-PE to generate N-acyl-2-acyl-lysoPE retaining the acyl group at sn-2 position. Furthermore, intramolecular transacylation of PE by N-acyltransferase may also yield N-acyl-2-acyl-lysoPE, although the sn-1 position of this molecule would be quickly subjected to reacylation [3] .
In mammals, the PLA 2 family comprises at least 19 isoenzymes, which are categorized into four families; sPLA 2 s, cPLA 2 s, Ca 2 + -independent PLA 2 s and platelet-activating factor acetylhydrolases [38] [39] [40] . We examined the contribution of PLA 2 isoenzymes other than sPLA 2 -IB to the hydrolysis of N-acyl-PE with recombinant enzymes of several representative PLA 2 s. The results showed that not only sPLA 2 -IB, but also sPLA 2 -IIA and sPLA 2 -V could hydrolyse N-palmitoyl-PE at comparable rates to the hydrolysis of PE, one of the most common substrates of PLA 2 . Thus PLA 1 /PLA 2 activity in different organs (Figure 1 ) may be attributed to different PLA 2 isoenzymes. Since sPLA 2 s, especially sPLA 2 -IIA, are up-regulated at various inflamed sites and implicated in the inflammatory processes [39] , the pathway via N-acyl-lysoPE might be involved in the production of anti-inflammatory NAEs at the inflamed sites. In contrast, sPLA 2 -X and cPLA 2 α hardly hydrolysed N-palmitoyl-PE, implying that PLA 2 isoenzymes may be functionally classified in terms of the capability of hydrolysing N-acyl-PE.
We found a lysoPLD activity hydrolysing N-acyl-lysoPE to NAE in various tissues of rat. One of the most interesting findings in the present study is the presence of N-acyl-lysoPE-hydrolysing lysoPLD enzyme distinct from the N-acyl-PE-hydrolysing PLD enzyme. This proposal is based on the differences in tissue distribution, inhibitory effect of MAFP, and effect of octyl glucoside on the solubilization between these two enzyme activities (Figures 4  and 5 ). As to the tissue distribution in rat, it was reported previously that the PLD activity was the highest in the heart, followed by the brain and testis [22, 35] . In contrast, in the present study we revealed a relatively low lysoPLD activity in the heart, in comparison with the brain and testis (Figure 4) . Since recombinant N-acyl-PE-hydrolysing PLD of mouse had a low hydrolysing activity toward N-acyl-lysoPE [20] , the observed lysoPLD activities for N-acyl-lysoPE may be partly attributed to the PLD enzyme rather than the lysoPLD enzyme. Indeed, the brain lysoPLD activity for N-acyl-lysoPE was not completely inhibited by MAFP, even at the highest concentration tested, and the remaining activity might be derived from PLD which was insensitive to MAFP ( Figure 5A ). Furthermore, a previous study with the microsome of dog brain reported that Triton X-100 stimulated the hydrolysis of N-acyl-PE to NAEs, but inhibited that of N-acyl-lysoPE [21] . This observation may provide further support for the presence of a lysoPLD enzyme distinct from the N-acyl-PE-hydrolysing PLD enzyme.
Recently, a lysoPLD releasing LPA (lysophosphatidic acid) from lysophosphatidylcholine was purified from plasma and identified to be a soluble form of autotaxin, a member of the ectonucleotide pyrophosphatase/phosphodiesterase family [41, 42] . Autotaxin is released extracellularly after the intramolecular cleavage and it exerts its enzymic activity outside the cells [43] , whereas the brain N-acyl-lysoPE-hydrolysing lysoPLD was tightly bound to the membrane and the efficiency of solubilization was poor even in the presence of octyl glucoside (Figure 5B) . Further investigations including the protein purification and cDNA cloning are required for its molecular characterization.
It has been a matter of debate whether or not an anandamideselective biosynthetic pathway exists in animal tissues. The N-acyl-PE-hydrolysing PLD was reported not to show selectivity in terms of N-acyl species [20, 44] . In the present study, N-arachidonoyl-PE and N-arachidonoyl-lysoPE as precursors of anandamide could be substrates of sPLA 2 -IB and lysoPLD respectively, but their reaction rates were similar to those for N-palmitoyl-PE and N-palmitoyl-lysoPE respectively. Since both N-palmitoylethanolamine and anandamide were produced at the same rate in this pathway, other NAEs would be then expected to be produced and exert their biological activity as a group (rather than as individual molecular species). Further investigation will be necessary to elucidate the possible presence of the anandamideselective biosynthetic pathway.
It is noted that the hydrolysis of N-acyl-lysoPE by lysoPLD resulted in the production of LPA, in addition to NAEs. LPA is mitogenic and angiogenic, and is implicated in the progression of cancer through its G-protein-coupled receptors [45] . On the other hand, NAEs were shown to have anti-tumour activity [46] . It is interesting that the pathway discussed in the present study simultaneously produces these two classes of bioactive lipids, which have apparently opposite effects on cancer cells.
In summary, we investigated for the first time the PLA 2 and lysoPLD enzymes responsible for the possible biosynthetic route of NAEs via N-acyl-lysoPE. Not all, but several sPLA 2 isoenzymes were found to participate in this pathway, and lysoPLD was suggested to be a distinct enzyme from the N-acyl-PE-hydrolysing PLD. The present study gives a further insight into the understanding of the biosynthesis and physiological roles of NAEs.
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